Clinical Trial

A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus

Name: A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus — clinical trial record (NCT06535412)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

The purpose of this study is to evaluate the efficacy and safety of IMC-002 and IMM0306S in the treatment of active SLE.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2024-07-30.

Status change: Not Yet Recruiting → Recruiting 2026-06-25

Trial Details

NCT Number	NCT06535412
Lead Sponsor	ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.
Conditions	Systemic Lupus Erythematosus
Enrollment	218 participants
Start Date	2024-10-10
Primary Completion	2028-12-17 (estimated)
Study Completion	2028-12-17 (estimated)
Updated on ClinicalTrials.gov	2026-06-29